Information Provided By:
Fly News Breaks for July 25, 2017
DGX
Jul 25, 2017 | 07:54 EDT
Canaccord analyst Mark Massaro said Quest Diagnostics continues to execute on its strategic initiatives and as a result expects positive Q2 results. The analyst views Quest as a steadily growing, defensive, free cash flow rich stock with a clear pathway for accelerating top-line growth, ongoing cost improvements, and sound capital deployment. Massaro reiterated his Buy rating and $118 price target on Quest Diagnostics shares.
News For DGX From the Last 2 Days
There are no results for your query DGX